Case Report

A Case of Statin-Induced Rhabdomyolysis in a 45-Year-Old Patient with Chronic Kidney Disease

DOI https://doi.org/10.70302/jpsim.v6i2.2538
Received: 11 Dec 2024 Revised: 02 Feb 2025 Accepted: 15 May 2025 Published Online: 05 Jun 2025

Abstract

Statin-induced rhabdomyolysis is a rare but potentially life-threatening condition, especially in patients with chronic kidney disease (CKD). This case report describes a 45-year-old male with CKD stage 5 who developed severe muscle pain, weakness, and dark urine after six months of atorvastatin therapy for dyslipidemia. Laboratory findings revealed markedly elevated creatine kinase (CK) levels, myoglobinemia, and myoglobinuria. Atorvastatin was immediately discontinued, and the patient received aggressive intravenous hydration. His symptoms and CK levels gradually improved without acute kidney injury. This case underscores the importance of vigilance in prescribing statins to CKD patients and highlights the need for prompt recognition and management of rhabdomyolysis. Clinicians should prioritize alternative lipid-lowering strategies for high-risk patients.

Keywords
Rhabdomyolysis Statins Chronic Kidney Disease Adverse Drug Reaction.

How to Cite This Article

Banaras F, Khan I, Khan A, Marrium B, Altaf N. A Case of Statin-Induced Rhabdomyolysis in a 45-Year-Old Patient with Chronic Kidney Disease. J Pak Soc Intern Med. 2025;6(2):197–199. doi:10.70302/jpsim.v6i2.2538

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2(3):210-8.
  2. Nseir G, El Douaihy Y, Mahamid M, Abu-Raya B, Sub-Laban K, Mograbi J. Statin-induced rhabdomyolysis in patients with chronic kidney disease. Am J Med Sci. 2020;360(4):386-91.
  3. Dragos D, Pruteanu D, Constantin R. High-dose statin associated with rhabdomyolysis, acute kidney injury, cholestatic liver injury, and thrombocytopenia. J Nephrol Kidney Dis. 2017;1(1):1001.
  4. Harel Z, Jeyakumar N, Smith G, Ray JG, Clemens KK, Juurlink DN. Rhabdomyolysis and Sodium-Glucose–Linked Transport Inhibitors in Patients Taking Statins. JAMA Network Open. 2024 Nov 4;7(11):e2446641.
  5. Nikolic D, Banach M, Chianetta R, Luzzu LM, Pantea Stoian A, Diaconu CC, et al. An overview of statin-induced myopathy and perspectives for the future. Exp Opin drug Safety. 2020;19(5):601-15.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2025 Journal of Pakistan Society of Internal Medicine.